The transcription factor FOXM1 is overexpressed in many human cancers,
including liver, stomach, prostate, brain, breast, lung, colon, pancreas, cervix, ovary
and nervous system. Recent data have demonstrated that FOXM1 is involved in cell
initiation, progression, and metastasis and in responses to anticancer drugs. In this review, the effects of FOXM1 on gastric
cancer, especially the function and regulation of FOXM1 in tumorigenesis and clinical chemotherapy, will be summarized
and discussed together with recent relevant patents on the role of FOXM1 in tumor therapy.